First Trust SMID Growth Strength ETF
Key Statistics
Historical Performance
Total return including reinvested distributions, from adjusted closing prices.
Price History
Price history is being compiled for this fund.
Top Holdings
Top 25 holdings as of Mar 31, 2026 · source: SEC N-PORT. Full holdings & prospectus →
About FSGS
The Fund will normally invest at least 90% of its net assets (plus any borrowings for investment purposes) in the securities that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate, before fees and expenses, the performance of the Index. The Index is owned and was developed and sponsored by Nitrogen Wealth, Inc. (the “Index Provider”). The Index Provider is a financial technology company that develops platforms to capture quantitative measurements of client and portfolio risk for investment advisors. The Index Provider has retained Nasdaq, Inc. to calculate and maintain the Index. Nasdaq, Inc. may, from time to time, exercise reasonable discretion as it deems appropriate in order to ensure Index integrity.According Nasdaq Inc., the Index seeks to create a diversified portfolio of dividend-paying securities. According to Nasdaq,Inc., to be eligible for inclusion in the Index, a security must be a constituent of the Nasdaq US 700 Small CapTM Index (the “Base Index”) and have paid a dividend in the trailing twelve months (based on ex-date). The Base Index is a rules-based index designed to measure stock market performance of securities ranked from 1101 to 1800 by full market capitalization of the NASDAQ US Benchmark Index, as determined by Nasdaq, Inc. The securities of companies represented in the Index generally have market capitalizations that are consistent with the name of the Index. The Index may be composed of, but not limited to, common stocks and real estate investment trusts (“REITs”).According to Nasdaq, Inc., security selection for the Index will be conducted in the following manner:1.The selection universe for the Index begins with all eligible securities in the Base Index. All such securities are classified at their industry level, as defined by the Industry Classification Benchmark.2.The weight of each industry in the Index is assigned to be the aggregate value of the industry in the Base Indexdivided by aggregate Base Index market value of all industries represented in the Index.3.Issuers that have not paid a dividend in the trailing 12 months are screened out.4.Each security within an industry is given an equal weight.The Index is rebalanced and reconstituted quarterly and the Fund will make corresponding changes to its portfolio shortly after the Index changes are made public. The Index’s quarterly rebalance and reconstitution schedule may cause the Fund to experience a higher rate of portfolio turnover. The Fund will be concentrated in an industry or a group of industries to the extent that the Index is so concentrated. As of June 28, 2024, the Index was composed of 325 securities with market capitalization ranges from $503.39 million to $7.66 billion. The Fund's investments will change as the Index changes and, as a result, the Fund may have significant investments in jurisdictions or investment sectors that it may not have had as of June 28, 2024. To the extent the Fund invests a significant portion of its assets in a given jurisdiction or investment sector, the Fund may be exposed to the risks associated with that jurisdiction or investment sector.
FSGS News
- Short Interest in First Trust SMID Growth Strength ETF (NASDAQ:FSGS) Decreases By 74.9%
- Folia Health Launches FSGS PULSE Study to Generate a More Complete Understanding of FSGS Disease Burden and Treatment
- Folia Health Launches FSGS PULSE Study to Generate a More Complete Understanding of FSGS Disease Burden and Treatment
- (FSGS) and the Role of Price-Sensitive Allocations
- Responsive Playbooks and the FSGS Inflection
- DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
- DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
- Responsive Playbooks and the FSGS Inflection
- Understanding the Setup: (FSGS) and Scalable Risk
- The Technical Signals Behind (FSGS) That Institutions Follow
- Dimerix licenses DMX-200 rights in Asia to Everest Medicines in deal worth up to A$481 million
- Dimerix licenses DMX-200 rights in Asia to Everest Medicines in deal worth up to A$481 million
Data for FSGS is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.